Premium
The Use of Continuous Subcutaneous Octreotide Infusion in Brittle Type 1 Diabetic Patients
Author(s) -
Bello F.,
Falko J. M.,
O'Dorisio T. M.,
Osei K.
Publication year - 1991
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1991.tb01615.x
Subject(s) - medicine , ketonuria , octreotide , diabetic ketoacidosis , diabetes mellitus , continuous infusion , surgery , type 1 diabetes , anesthesia , endocrinology , somatostatin
Two Type 1 diabetic patients with brittle diabetes were successfully treated using continuous SC octreotide (Sandostatin) infusion (200 μg 24‐h −1 ) for 6 months and 12 months. When the analogue was discontinued, rapid deterioration in glucose control and ketonuria recurred in one patient and diabetic ketoacidosis in the other. These were corrected after reinstitution of the analogue.